Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers

Marjolein Y. A. M. Kroonen, Jeroen V. Koomen, Sergei I. Petrykiv, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Jasper Stevens*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

5 Citaten (Scopus)
102 Downloads (Pure)

Samenvatting

Aims: To quantitate the consistency of an individual's plasma exposure to dapagliflozin upon re-exposure, and to investigate whether the individual's systemic exposure to dapagliflozin explains inter-individual variation in response to dapagliflozin with regard to multiple renal risk markers. Methods: Data were used from a crossover randomized clinical trial that assessed the albuminuria-lowering effect of dapagliflozin in 33 people with type 2 diabetes and elevated albuminuria. Fifteen participants were exposed twice to dapagliflozin. Trough plasma concentrations of dapagliflozin were measured for each participant at steady state. Dapagliflozin plasma concentrations were measured by liquid chromatography tandem mass spectrometry, and pharmacokinetic characteristics were simulated based on a population pharmacokinetic model. Linear mixed-effects models were used to quantify the exposure–response relationships. Results: The median plasma concentration after first and second exposure to dapagliflozin was 5.3 ng/mL vs 4.6 ng/mL, respectively (P = 0.78). Lin's concordance correlation coefficient between occasions was 0.73 (P < 0.0021). Every 100 ng.h/mL increment in area under the dapagliflozin plasma concentration curve was associated with a decrease in log-transformed urinary albumin:creatinine ratio (β = −5.9, P < 0.01), body weight (β = −0.3, P < 0.01) and estimated glomerular filtration rate (β = −0.7, P = 0.01) and an increase in urinary glucose excretion (β = 17.0, P < 0.001). Conclusion: An individual's exposure to dapagliflozin is consistent upon re-exposure and correlates with pharmacodynamic response in renal risk markers.

Originele taal-2English
Pagina's (van-tot)916-921
Aantal pagina's6
TijdschriftDiabetes obesity & metabolism
Volume22
Nummer van het tijdschrift6
Vroegere onlinedatum27-jan.-2020
DOI's
StatusPublished - 17-feb.-2020

Vingerafdruk

Duik in de onderzoeksthema's van 'Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers'. Samen vormen ze een unieke vingerafdruk.

Citeer dit